Nusivertib + Ruxolitinib + Momelotinib
Phase 1/2Recruiting 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myelofibrosis
Conditions
Myelofibrosis
Trial Timeline
Dec 16, 2019 → Apr 30, 2030
NCT ID
NCT04176198About Nusivertib + Ruxolitinib + Momelotinib
Nusivertib + Ruxolitinib + Momelotinib is a phase 1/2 stage product being developed by Sumitomo Pharma for Myelofibrosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04176198. Target conditions include Myelofibrosis.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04176198 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Myelofibrosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ruxolitinib + Abemaciclib | Eli Lilly | Phase 1 | 33 |
| Ruxolitinib + Navitoclax | AbbVie | Phase 2 | 52 |
| ABBV-744 + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Placebo for Navitoclax + Ruxolitinib + Navitoclax | AbbVie | Phase 3 | 77 |
| Mivebresib + Navitoclax + Ruxolitinib | AbbVie | Phase 1 | 33 |
| Navitoclax + Venetoclax | AbbVie | Pre-clinical | 23 |
| Navitoclax + Ruxolitinib + Best Available Therapy (BAT) | AbbVie | Phase 3 | 77 |
| NS-018 + Best Available Therapy | Nippon Shinyaku | Phase 2 | 52 |
| AZD1480 | AstraZeneca | Phase 1 | 33 |
| Bomedemstat | Merck | Phase 2 | 52 |
| Peginterferon alfa-2a | Merck | Phase 2 | 52 |
| Bomedemstat | Merck | Phase 1/2 | 41 |
| MBG453 + NIS793 + Spartalizumab + Decitabine | Novartis | Phase 1 | 33 |
| PIM447 + Ruxolitinib + LEE011 | Novartis | Phase 1 | 33 |
| LDE225 + INC424 | Novartis | Phase 1/2 | 41 |
| Imatinib mesylate | Novartis | Phase 2 | 52 |
| Ruxolitinib + Siremadlin + Crizanlizumab + Sabatolimab + Rineterkib + NIS793 | Novartis | Phase 1/2 | 41 |
| Ruxolitinib + Ruxolitinib Placebo | Novartis | Phase 3 | 77 |
| Ruxolitinib | Novartis | Pre-clinical | 23 |
| ruxolitinib | Novartis | Phase 2 | 52 |